Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus JENLOGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus JENLOGA.
ENSKYCE vs JENLOGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
350 mg orally once daily with food.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Category C
Category C
Oral Contraceptive
Oral Contraceptive